Movement Alert|ImmunityBio, Inc. Intraday Rise 4.31% in Regular Trading, Anktiva overseas rollout and clinical progress support sentiment

Market Focus
Nov 18

On November 18, ImmunityBio, Inc. rose 4.31% in Regular Trading, trading at $6.54 per share, with turnover of $13.0768 million.

The move aligned with continued investor focus on recent Anktiva-related developments, including Israeli regulatory approval, first European patient treatments, and a bladder cancer registrational trial meeting its primary endpoint, which supported product commercialization expectations despite a recent quarterly miss.

Recent updates showed Anktiva with BCG was approved by the Israeli Ministry of Health for certain BCG-unresponsive non-muscle invasive bladder cancer patients, with the registration license expected within weeks. The company also said first patients in Europe had been treated following conditional European authorization, while its registrational NMIBC trial enrolled 370 subjects across more than 75 sites and showed statistically significant efficacy improvement versus BCG alone. These developments came after third-quarter revenue of $48.841 million missed the $59.25 million consensus and net loss per share widened to $0.18 from $0.07 a year earlier, but product-side progress appeared to remain the more immediate support for the shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10